ipos0_l

Sanofi will pay Regeneron $582m in deal restructuring

pharmafile | January 7, 2019 | News story | Sales and Marketing |  Deals, Regeneron, Sanofi, biotech, pharma 

French pharmaceutical giant Sanofi will pay US biotech Regeneron $582 million, as part of a restructuring of an earlier deal between the two firms.

It is hoped that the new arrangement will offer Sanofi increased flexibility in advancing its early-stage immuno-oncology pipeline independently.

Meanwhile Regeneron will retain all rights to its other immuno-oncology discovery and development programmes.

Advertisement

Sanofi will pay Regeneron an initial sum of $462 million, which will cover Sanofi’s share of the costs for the immuno-oncology discovery programme for the last quarter of 2018, as agreed under the original terms of the deal set in 2015.

Sanofi will also pay an additional $120 million, which will cover other development costs for two selected clinical-stage bispecific antibodies, plus the termination fee for the other programs under the original immuno-oncology agreement. The original deal was scheduled to end in approximately mid-2020.

The agreement will secure Sanofi’s right to opt-in to the BCMAxCD3 and MUC16xCD3 bispecific programs when proof of concept is achieved or when the allocated funding is expended.

Louis Goss

Related Content

Arkin Capital closes $100m fund for pre-clinical and early clinical-stage biotech

Arkin Capital has announced the closing of Arkin Bio Ventures III, a $100m fund designed …

Cellbyte raises $2.75m to fund pharma drug launch platform

Cellbyte has announced that it has raised $2.75m in seed funding for the streamlining of …

Sanofi and Regeneron’s Dupixent receives CHMP recommendation for chronic spontaneous urticaria

Sanofi and Regeneron have received a positive opinion from the European Medicines Agency’s (EMA) Committee …

The Gateway to Local Adoption Series

Latest content